OKYO Pharma (OKYO) News Today $2.35 +0.07 (+3.07%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.28 -0.08 (-3.19%) As of 08/29/2025 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKYO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period OKYO Pharma (NASDAQ:OKYO) Raised to "Hold" at Wall Street ZenAugust 10, 2025 | marketbeat.comDauntless Investment Group LLC Invests $2.53 Million in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO)July 29, 2025 | marketbeat.comOKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMIJuly 19, 2025 | proactiveinvestors.comOKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMIJuly 19, 2025 | proactiveinvestors.comOKYO Slides Despite Fresh R&D FundingJuly 17, 2025 | baystreet.caOKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal PainJuly 17, 2025 | finance.yahoo.comOKYO Pharma Secures $1.9 Million to Boost Urcosimod DevelopmentJuly 17, 2025 | tipranks.comOKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapyJuly 17, 2025 | proactiveinvestors.comOKYO reports top-line data from neuropathic corneal pain therapy trialJuly 17, 2025 | finance.yahoo.comOKYO Pharma shares surge following promising Phase 2 data for eye pain treatmentJuly 16, 2025 | msn.comPositive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track DesignationJuly 16, 2025 | tipranks.comOKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal PainJuly 16, 2025 | tipranks.comOKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal painJuly 16, 2025 | proactiveinvestors.comOKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal PainJuly 16, 2025 | globenewswire.comOKYO Pharma (NASDAQ:OKYO) Trading Up 1% - Here's WhyJuly 10, 2025 | marketbeat.comOKYO Pharma (NASDAQ:OKYO) Shares Down 13.7% - Should You Sell?June 18, 2025 | marketbeat.comOKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insidersJune 14, 2025 | uk.finance.yahoo.comOKYO Pharma poised for breakout as Phase 2 trial nears results: analystsJune 11, 2025 | proactiveinvestors.comGoldman Small Cap Research Issues New Research Update on OKYO Pharma Limited | OKYO Stock NewsJune 11, 2025 | gurufocus.comTokyo stocks edge down amid caution over U.S.-China trade tensionsJune 3, 2025 | msn.comOKYO Pharma (NASDAQ:OKYO) Stock Price Up 0.5% - Should You Buy?May 28, 2025 | marketbeat.comOKYO Pharma CEO to present drug research for debilitating eye pain at Boston summitMay 19, 2025 | proactiveinvestors.comOKYO Pharma CEO to Present at Boston Drug Discovery SummitMay 19, 2025 | tipranks.comOKYO Pharma to Present at the GPCRs-Targeted Drug Discovery SummitMay 19, 2025 | globenewswire.comOKYO moves toward FDA talks after eye drug trial – ICYMIMay 2, 2025 | proactiveinvestors.comOKYO moves toward FDA talks after eye drug trial – ICYMIMay 2, 2025 | proactiveinvestors.comOKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal painMay 1, 2025 | proactiveinvestors.comOKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal painApril 30, 2025 | proactiveinvestors.comOKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal PainApril 30, 2025 | tipranks.comOKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal PainApril 30, 2025 | globenewswire.comOKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMIApril 5, 2025 | proactiveinvestors.comOKYO Pharma confirms stability of drug candidateApril 2, 2025 | uk.investing.comOKYO Pharma reports long-term shelf stability of corneal pain treatmentMarch 31, 2025 | proactiveinvestors.comOKYO Pharma Announces Positive Data in Long-Term Stability of UrcosimodMarch 31, 2025 | globenewswire.comOKYO Pharma Limited (NASDAQ:OKYO) Short Interest UpdateMarch 18, 2025 | marketbeat.comOKYO Pharma Files Application for Fast Track Designation for Urcosimod in Treatment of Neuropathic Corneal PainMarch 12, 2025 | nasdaq.comOKYO Pharma seeks FDA Fast Track for eye pain drugMarch 12, 2025 | uk.investing.comOKYO Pharma seeks FDA fast track for eye pain treatmentMarch 12, 2025 | uk.investing.comOKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatmentMarch 10, 2025 | proactiveinvestors.comOkyo Pharma files for FTD with FDA for urcosimodMarch 10, 2025 | markets.businessinsider.comOKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal PainMarch 10, 2025 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for OKYO Pharma Limited Sponsored ADR (OKYO)February 18, 2025 | markets.businessinsider.comBuy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market PotentialFebruary 14, 2025 | tipranks.comOKYO Pharma secures USAN designation ‘urcosimod' for lead assetFebruary 12, 2025 | proactiveinvestors.comOKYO Pharma’s Lead Asset OK-101 Receives USAN as UrcosimodFebruary 12, 2025 | tipranks.comYi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory ChallengesFebruary 10, 2025 | tipranks.comOKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believeJanuary 31, 2025 | proactiveinvestors.comOKYO Pharma insiders acquire sharesJanuary 31, 2025 | proactiveinvestors.comOKYO Pharma Executives Increase Shareholdings, Affirming Market ConfidenceJanuary 31, 2025 | tipranks.comOKYO Pharma Announces Chairman and CEO Acquire SharesJanuary 31, 2025 | globenewswire.com Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OKYO Media Mentions By Week OKYO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OKYO News Sentiment▼1.881.11▲Average Medical News Sentiment OKYO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OKYO Articles This Week▼11▲OKYO Articles Average Week Get the Latest News and Ratings for OKYO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for OKYO Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ADCT News ALDX News FULC News CGC News BNTC News CTMX News CADL News AMRN News LRMR News DRUG News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OKYO) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OKYO Stock Alerts